Skip to main content

Advertisement

SpringerLink
Log in

Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report the clinical experience of intravitreal ranibizumab administered as needed for the treatment of neovascular age-related macular degeneration (AMD).

Methods

We retrospectively reviewed the charts of 41 patients (41 eyes) with occult and minimally classic neovascular membrane in AMD. Patients received intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Forty-one eyes were retreated at the discretion of the treating physician on an as-needed basis after the first injection, instead of initially giving three monthly injections. The main outcomes measured were change in mean visual acuity and central retinal thickness, and the total number of injections received by patients during the 12 months.

Results

At 12 months, the mean logarithm of the minimum angle of resolution (logMAR) visual acuity improved by 0.078 logMAR units (P = 0.046) and the mean central retinal thickness decreased by 85.7 μm (P < 0.001). Thirty of 41 eyes (73.2%) avoided any loss of vision, and 20 eyes (48.8 %) showed improved visual acuity. A mean of 4.07 injections were given over the 12 months.

Conclusions

Ranibizumab administered on an as-needed basis may stabilize visual acuity in patients with neovascular AMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.

    Article  PubMed  CAS  Google Scholar 

  2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.

    Article  PubMed  CAS  Google Scholar 

  3. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113:633–642.

    Article  PubMed  Google Scholar 

  4. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration; PIER study year 1. Am J Ophthalmol 2008;145:239–248.

    Article  PubMed  CAS  Google Scholar 

  5. Fung AE, Laiwani GA, Resenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566–583.

    Article  PubMed  CAS  Google Scholar 

  6. Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica 2008;222:321–323.

    Article  PubMed  CAS  Google Scholar 

  7. Heier JS, Boyer DS, Gulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1932–1942.

    Article  Google Scholar 

  8. Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet 2008;372:1835–1845.

    Article  PubMed  CAS  Google Scholar 

  9. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007;29:1850–1861.

    Article  PubMed  CAS  Google Scholar 

  10. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Ranibizumab for neovascular age-related macular degeneration. Am J Health Syst Pharm 2008;65:1805–1814.

    Article  PubMed  CAS  Google Scholar 

  11. Falkenstein IA, Cochran DE, Azen SP, et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 2008;115:319–323.

    Article  PubMed  Google Scholar 

  12. Sloan LL. New test charts for the measurement of visual acuity at far and near distances. Am J Ophthalmol 1959;48:807–813.

    PubMed  CAS  Google Scholar 

  13. Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36:748–755.

    Article  PubMed  Google Scholar 

  14. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636–1641.

    Article  PubMed  CAS  Google Scholar 

  15. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1–9.

    Article  PubMed  CAS  Google Scholar 

  16. Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007;17:230–237.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Science, St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

    Seungbum Kang & Young-Jung Roh

  2. Department of Ophthalmology and Visual Science, St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 62 Yoido-dong, Youngdungpo-gu, Seoul, 150-713, Korea

    Young-Jung Roh

Authors
  1. Seungbum Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Young-Jung Roh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-Jung Roh.

About this article

Cite this article

Kang, S., Roh, YJ. Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration. Jpn J Ophthalmol 55, 123–127 (2011). https://doi.org/10.1007/s10384-010-0910-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-010-0910-1

Keywords

Search

Navigation